Clinical Trial Update: A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating dasatinib in chronic myeloid leukemia in chronic phase reports results related to complete molecular response.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Kanto CML Study Group | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED